Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Ainara Soria
Based on 8 articles published since 2009
(Why 8 articles?)
||||

Between 2009 and 2019, A. Soria wrote the following 8 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline SEOM clinical guideline for the management of malignant melanoma (2017). 2018

Berrocal, A / Arance, A / Castellon, V E / de la Cruz, L / Espinosa, E / Cao, M G / Larriba, J L G / Márquez-Rodas, I / Soria, A / Algarra, S M. ·Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces 2, 46014, Valencia, Spain. berrocal.alf@gmail.com. · Hospital Clinic I Provincial de Barcelona, Barcelona, Spain. · Hospital Torrecárdenas, Almería, Spain. · Complejo Hospitalario Regional Virgen Macaren, Seville, Spain. · Hospital Universitario la Paz, Madrid, Spain. · Hospital Universitario Quirón Dexeus, Barcelona, Spain. · Hospital Universitario Clínico San Carlos, Madrid, Spain. · Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Hospital Universitario Ramón y Cajal, Madrid, Spain. · Clínica Universitaria de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #29116432.

ABSTRACT: All melanoma suspected patients must be confirmed histologically and resected. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon could be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 containing therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 containing therapy. Up to 10 years follow up is reasonable for melanoma patients with dermatologic examinations and physical exams.

2 Review [Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer]. 2015

Iglesias, Pedro / Soria, Ainara / Díez, Juan José. ·Unidad de Neuroendocrinología y Tumores Endocrinos, Servicio de Endocrinología y Nutrición, Hospital Ramón y Cajal, Madrid, España. Electronic address: piglo65@gmail.com. · Servicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, España. · Unidad de Neuroendocrinología y Tumores Endocrinos, Servicio de Endocrinología y Nutrición, Hospital Ramón y Cajal, Madrid, España; Departamento de Medicina, Universidad de Alcalá de Henares, Alcalá de Henares, Madrid, España. ·Med Clin (Barc) · Pubmed #25851909.

ABSTRACT: -- No abstract --

3 Article Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. 2018

Gonzalez-Cao, Maria / Mayo de Las Casas, Clara / Jordana Ariza, Nuria / Manzano, Jose L / Molina-Vila, Miguel Á / Soriano, Virtudes / Puertolas, Teresa / Balada, Ariadna / Soria, Ainara / Majem, Margarita / Montagut, Clara / Muñoz, Eva / Rodriguez-Abreu, Delvys / Perez, Elisabeth / Garcia, Almudena / Cortes, Javier / Drozdowskyj, Ana / Karachaliou, Niki / Rosell, Rafael / Anonymous5291039. ·Laboratory of Oncology, Institute of Oncology Dr Rosell (IOR), University Hospital Quirón Dexeus. · Catalan Institute of Oncology, Germans Trias i Pujol Hospital, Badalona. · IVO Fundation, Carrer del Professor Beltrán Báguena, Valencia. · Miguel Servet Hospital, Paseo Isabel la Católica, Zaragoza. · Ramon y Cajal Hospital. · Sant Pau Hospital, Carrer de Sant Quintí. · Del Mar Hospital-IMIM Passeig Marítim. · Vall D'Hebron Institute of Oncology (VHIO), Passeig de la Vall d'Hebron, Barcelona. · University Hospital de Gran Canaria, Las Palmas. · Costa del Sol Hospital, Marbella. · Marques de Valdecilla Hospital, Santander, Spain. · Pivotal SL, Madrid. ·Melanoma Res · Pubmed #29481492.

ABSTRACT: Serial analysis of BRAF mutations in circulating-free DNA (cfDNA) could be of prognostic value in melanoma patients. We collected blood samples from 63 advanced BRAFV600E/K melanoma patients and determined BRAFV600E/K status in cfDNA using a quantitative 5'-nuclease PCR-based assay. Levels of BRAF mutation in pre-cfDNAs were associated significantly with tumour burden, progression-free survival and overall survival. Changes in BRAF status in cfDNA after initiation of treatment (early-cfDNA) had a significant correlation with outcome. In patients with persistent BRAF mutations (n=12), progression-free survival and overall survival were 3.5 months [95% confidence interval (CI): 1.6-4.6] and 5.3 months (95% CI: 3.4-8.1) compared with 16.6 months (95% CI: 8.2-22.3) and 21.9 months (95% CI: 10.2-NR) in patients with BRAF negativization (n=16), and 15.1 months (95% CI: 2.3-NR) and NR (95% CI: 5.1-NR) in patients who maintained their initial negative status (n=12) (P<0.0001). The median duration of response in patients with radiological response, but persistence of BRAFV600 in early-cfDNA (n=5) was 4 months. Our study indicates that serial BRAF testing in the blood of advanced melanoma identifies patients refractory to therapy.

4 Article Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study. 2017

Martín Algarra, Salvador / Soriano, Virtudes / Fernández-Morales, Luis / Berciano-Guerrero, Miguel-Ángel / Mujika, Karmele / Manzano, José Luis / Puértolas Hernández, Teresa / Soria, Ainara / Rodríguez-Abreu, Delvys / Espinosa Arranz, Enrique / Medina Martínez, Javier / Márquez-Rodas, Ivan / Rubió-Casadevall, Jordi / Ortega, María Eugenia / Jurado García, José Miguel / Lecumberri Biurrun, María José / Palacio, Isabel / Rodríguez de la Borbolla Artacho, María / Altozano, Javier Pérez / Castellón Rubio, Victoria Eugenia / García, Almudena / Luna, Pablo / Ballesteros, Anabel / Fernández, Ovidio / López Martín, Jose Antonio / Berrocal, Alfonso / Arance, Ana. ·Medical Oncology, Clínica Universidad de Navarra, Pamplona. · Instituto Valenciano de Oncología, Valencia. · Medical Oncology, Parc Taulí Sabadell Hospital Universitario, Sabadell. · Oncología Intercentros, Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV) and Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga. · Onkologikoa, Instituto Oncológico de Kutxa, San Sebastian. · Instituto Catalán de Oncología, ICO-Badalona, Hospital Germans Trías I Pujol, Barcelona. · Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza. · Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid. · Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria. · Medical Oncology, Hospital Universitario La Paz, Madrid. · Medical Oncology, Hospital Virgen de la Salud, Toledo. · Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid. · Instituto Catalán de Oncología Girona, Girona. · Medical Oncology, Hospital Universitario Arnau de Vilanova, Lleida. · Medical Oncology, Hospital Universitario San Cecilio, Granada. · Medical Oncology, Complejo Hospitalario de Navarra, Pamplona. · Medical Oncology, Hospital Universitario Central de Asturias, Oviedo. · Medical Oncology, Hospital Universitario Nuestra Señora de Valme, Sevilla. · Medical Oncology, Hospital General Universitario de Elche, Alicante. · Medical Oncology, Complejo Hospitalario Torrecárdenas de Almería, Almería. · Medical Oncology, Hospital Marqués de Valdecilla, Santander. · Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca. · Medical Oncology, Hospital Universitario La Princesa, Madrid. · Medical Oncology, Complejo Hospitalario Universitario Ourense, Ourense. · Medical Oncology, Hospital Universitario 12 de Octubre, Madrid. · Medical Oncology, Hospital General Universitario de Valencia, Valencia. · Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain. ·Medicine (Baltimore) · Pubmed #29384960.

ABSTRACT: The main objective of the study was to evaluate the efficacy and safety of dabrafenib alone or combined with trametinib for compassionate use in patients with metastatic melanoma.This retrospective, observational study involved 135 patients with unresectable stage IIIC or stage IV melanoma from an expanded-access program at 30 Spanish centers.Forty-eight patients received dabrafenib monotherapy and 87 received combination dabrafenib and trametinib; 4.4% and 95.6% of the patients had stage IIIC and IV melanoma, respectively. All patients showed BRAF mutations in their primary or metastatic lesions; 3 were positive for V600K while the remainder had V600E or V600+. A positive response to treatment was reported in 89.3% of the patients. Overall survival rates at 12 and 24 months were 59.6% (95% confidence interval [CI], 52.5-68.9%) and 36.4% (95% CI, 27.8-45%), respectively. Progression-free survival rates at 12 and 24 months were 39.3% (95% CI, 31.1-47.5%) and 21.6% (95% CI, 14.5-28.7%), respectively. Fifty-seven patients (42.2%) reported cutaneous toxicity of any type, mainly hyperkeratosis (14.8%) and rash (11.9%). The most frequent adverse events were pyrexia (27.4%), asthenia (19.3%), arthralgia (16.9%), and diarrhoea (13.2%).Our results suggest that both dabrafenib alone or in combination with trametinib are effective for compassionate use in terms of response and/or survival rates. However, differences in patients' prognostic features ought to be considered. No new findings were revealed regarding the safety profiles of either regimen. This is the first study to evaluate the efficacy of these 2 selective BRAF and mitogen-activated extracellular signal-regulated kinase inhibitors in a real-world setting in Spain.

5 Article Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. 2017

González-Cao, M / Arance, A / Piulats, J M / Marquez-Rodas, I / Manzano, J L / Berrocal, A / Crespo, G / Rodriguez, D / Perez-Ruiz, E / Berciano, M / Soria, A / Castano, A G / Espinosa, E / Montagut, C / Alonso, L / Puertolas, T / Aguado, C / Royo, M A / Blanco, R / Rodríguez, J F / Muñoz, E / Mut, P / Barron, F / Martin-Algarra, S / Anonymous4770892. ·Translational Cancer Research Unit, Dr. Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028, Barcelona, Spain. mgonzalezcao@oncorosell.com. · Hospital Clinic I Provincial, Barcelona, Spain. · Catalan Institute of Oncology, Barcelona, Spain. · Gregorio Marañón Institute of Health Research, Madrid, Spain. · Germans Trias I Pujol University Hospital, Barcelona, Spain. · General University Hospital, Valencia, Spain. · Burgos University Hospital, Burgos, Spain. · Insular University Hospital of Gran Canaria, Canary Islands, Spain. · Costa del Sol Hospital, Marbella, Malaga, Spain. · Regional University Hospital of Malaga, Malaga, Spain. · Ramony Cajal Hospital, Madrid, Spain. · Marqués de Valdecilla University Hospital, Santander, Spain. · La Paz University Hospital, Madrid, Spain. · Del Mar University Hospital, Barcelona, Spain. · Virgen de la Victoria Hospital, Malaga, Spain. · Miguel Servet University Hospital, Zaragoza, Spain. · San Carlos Hospital, Madrid, Spain. · Dr. Peset Hospital, Valencia, Spain. · Consorci Sanitari de Terrassa, Barcelona, Spain. · Clara Campal Hospital, Madrid, Spain. · Valld'Hebron University Hospital, Barcelona, Spain. · Son Llatzer University Hospital, Mallorca, Spain. · National Cancer Institute, Mexico City, Mexico. · Navarra University Clinic, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #28054320.

ABSTRACT: BACKGROUND: The programmed death (PD-1) inhibitor pembrolizumab has been recently approved for the treatment of advanced melanoma. We evaluated the clinical activity of pembrolizumab in melanoma patients treated under the Spanish Expanded Access Program. METHODS: Advanced melanoma patients who failed to previous treatment lines were treated with pembrolizumab 2 mg/kg every three weeks. Patients with brain metastases were not excluded if they were asymptomatic. Data were retrospectively collected from 21 centers in the Spanish Melanoma Group. RESULTS: Sixty-seven advanced melanoma patients were analyzed. Most patients were stage M1c (73.1%), had high LDH levels (55.2%) and had ECOG PS 1 or higher (59.7%). For cutaneous melanoma patients, median overall survival was 14.0 months; the 18-month overall survival rate was 47.1%. Overall response rate was 27%, including three patients with complete responses (6.5%). Median response duration was not reached, with 83.3% of responses ongoing (3.5 m+ to 20.4 m+). From ten patients included with brain metastases, four (40%) had an objective response, two (20%) of them achieved a complete response. Significant prognostic factors for overall survival were LDH level, ECOG PS and objective response. There were no serious adverse events. CONCLUSION: Although this was a heavily pretreated cohort, pembrolizumab activity at the approved dose and schedule was confirmed in the clinical setting with long-term responders, also including patients with brain metastases.

6 Article Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study. 2016

Espinosa, Enrique / Soriano, Virtudes / Malvehy, Josep / Berrocal, Alfonso / Martínez de Prado, Purificación / Quindós, María / Soria, Ainara / Márquez-Rodas, Iván / Palacio, Isabel / Cerezuela, Pablo / López-Vivanco, Guillermo / Alonso, Lorenzo / Samaniego, Elia / Ballesteros, Ana / Puértolas, Teresa / Díaz-Beveridge, Rodrigo / de la Cruz-Merino, Luis / López Castro, Rafael / López López, Rafael / Stevinson, Kendall / Del Barrio, Patricia / Tornamira, Maria V / Guillém, Vicente / Martín-Algarra, Salvador. ·aMedical Oncology Service, Hospital Universitario La Paz bMedical Oncology Service, Hospital Ramón y Cajal cMedical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañon dMedical Oncology Service, Hospital La Princesa eMedical Affairs, Merck Sharp & Dohme, Madrid fMedical Oncology Service, Instituto Valenciano de Oncología gMedical Oncology Service, Hospital General Universitario de Valencia hMedical Oncology Service, Hospital La Fe, Valencia iMedical Oncology Service, Hospital Clinic de Barcelona, Barcelona jMedical Oncology Service, Hospital de Basurto, Bilbao kMedical Oncology Service, Hospital Teresa Herrera, La Coruña lMedical Oncology Service, Hospital Central de Asturias, Oviedo mMedical Oncology Service, Hospital General Universitario Santa Lucía, Cartagena nMedical Oncology Service, Hospital de Cruces, San Vicente de Baracaldo oMedical Oncology Service, Hospital Universitario Virgen de la Victoria, Málaga pDermatology Service, Complejo Asistencial Universitario de León, León qMedical Oncology Service, Hospital Miguel Servet, Zaragoza rMedical Oncology Service, Hospital Virgen de la Macarena, Sevilla sMedical Oncology Service, Hospital Clínico Universitario de Valladolid, Valladolid tMedical Oncology Service, Hospital Clínico Universitario de Santiago, Santiago de Compostela uMedical Oncology Service, Clínica Universitaria de Navarra, Pamplona, Spain vGlobal Health Outcomes Research, Merck Sharp & Dohme, Kenilworth, New Jersey, USA. ·Melanoma Res · Pubmed #26958991.

ABSTRACT: Adjuvant interferon-α2b (IFN-α2b) has been studied extensively in clinical trials, but there have been few studies of real-world use. The aim of this study is to describe the IFN-α2b real-world patterns in patients with high-risk melanoma in Spain. This was a retrospective and multicentre chart review study of an unselected cohort of patients with melanoma at high risk for relapse (stage IIB/IIC/III) treated with IFN-α2b. Patterns were assessed in terms of dose and compliance to planned treatment. A survival analysis was carried out for the full population and according to Kirkwood scheme compliance and the presence of ulceration. Of 327 patients treated with IFN-α2b, 318 received a high-dose regimen following the standard Kirkwood scheme; thus, patterns are described for this regimen. A total of 121 (38%) and 88 (28%) patients had at least one dose reduction during the induction and maintenance phases, respectively. Dose delay was required in fewer than 10% of patients. A total of 78, 40 and 38% of the patients completed the induction phase, maintenance phase and completed treatment, respectively. The median progression-free and overall survival for the full population were 3.2 and 10.5 years, respectively. There were no differences in progression-free survival and overall survival according to Kirkwood scheme compliance and the presence of ulceration. The most frequent adverse events were neutropenia (31%) and fatigue (30%). High-dose IFN-α2b is the most frequently used regimen in Spain as an adjuvant systemic treatment for high-risk melanoma. Despite poor compliance, in this retrospective study, IFN-α2b treatment provided a benefit consistent with that described previously.

7 Article SEOM guidelines for the management of Malignant Melanoma 2015. 2015

Berrocal, A / Arance, A / Espinosa, E / Castaño, A G / Cao, M G / Larriba, J L G / Martín, J A L / Márquez, I / Soria, A / Algarra, S M. ·Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Avda. Tres Cruces 2, 46014, Valencia, Spain. berrocal.alf@gmail.com. · Hospital Clinic I Provincial de Barcelona, Barcelona, Spain. · Hospital Universitario la Paz, Madrid, Spain. · Hospital Universitario Marqués de Valdecilla, Santander, Spain. · Hospital Universitario Quirón Dexeus, Barcelona, Spain. · Hospital Universitario Clínico San Carlos, Madrid, Spain. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Hospital Universitario Ramón y Cajal, Madrid, Spain. · Clínica Universitaria de Navarra, Pamplona, Spain. ·Clin Transl Oncol · Pubmed #26669314.

ABSTRACT: All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams.

8 Article Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study. 2015

Márquez-Rodas, Iván / Martín González, Manuel / Nagore, Eduardo / Gómez-Fernández, Cristina / Avilés-Izquierdo, Jose Antonio / Maldonado-Seral, Cayetana / Soriano, Virtudes / Majem-Tarruella, Margarita / Palomar, Virginia / Maseda, Rocio / Martín-Carnicero, Alfonso / Puertolas, Teresa / Godoy, Elena / Cerezuela, Pablo / Ochoa de Olza, Maria / Campos, Begoña / Perez-Ruiz, Elisabeth / Soria, Ainara / Gil-Arnaiz, Irene / Gonzalez-Cao, Maria / Galvez, Elisa / Arance, Ana / Belon, Joaquin / de la Cruz-Merino, Luis / Martín-Algarra, Salvador / Anonymous731066. ·Servicio de Oncología Médica, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. · Servicio de Dermatología, Hospital Ramón y Cajal, Madrid, Spain. · Servicio de Dermatología, Instituto Valenciano de Oncología, Valencia, Spain. · Servicio de Dermatología, Hospital La Paz, Madrid, Spain. · Servicio de Dermatología, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. · Servicio de Deramtología, Hospital Universitario Central de Asturias, Oviedo, Spain. · Servicio de Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain. · Servicio de Oncología Médcica, Hospital de Sant Pau, Barcelona, Spain. · Servicio de Oncología Médica, Hospital General de Valencia, Valencia, Spain. · Servicio de Oncología Médica, Hospital de San Pedro, Logroño, Spain. · Servicio de Oncología, Hospital Universitario Miguel Servet, Zaragoza, Spain. · Servicio de Dermatología, Hospital de Cabueñes, Gijon, Spain. · Servicio de Oncología Médica, Hospital General Universitario Santa Lucia, Cartagena, Spain. · Servicio de Oncología Médica, Instituto Catalan de Oncología, Hospitalet, Spain. · Servicio de Oncología Médica, Hospital Lucus Augusti, Lugo, Spain. · Servicio de Oncología Médica, Hospital Costa del Sol, Marbella, Spain. · Servicio de Oncología Médica, Hospital Ramón y Cajal, Madrid, Spain. · Servicio de Oncología Medica, Hospital Reina Sofía, Tudela, Spain. · Servico de Oncología Médica, Instituto Dexeus, Barcelona, Spain. · Servicio de Oncología Médica, Hospital de Elda, Alicante, Spain. · Servicio de Oncología Medica, Hospital Clinic, Barcelona, Spain. · Servicio de Oncología Médica, Clínica Oncogranada, Granada, Spain. · Servicio de Oncología Médica, Hospital Virgen de la Macarena, Sevilla, Spain. · Departamento de Oncología, Clínica Universidad de Navarra, Pamplona, Spain. ·PLoS One · Pubmed #25874698.

ABSTRACT: INTRODUCTION: Familial history of melanoma is a well-known risk factor for the disease, and 7% melanoma patients were reported to have a family history of melanoma. Data relating to the frequency and clinical and pathological characteristics of both familial and non-familial melanoma in Spain have been published, but these only include patients from specific areas of Spain and do not represent the data for the whole of Spain. PATIENTS AND METHODS: An observational study conducted by the Spanish Group of Melanoma (GEM) analyzed the family history of patients diagnosed with melanoma between 2011 and 2013 in the dermatology and oncology departments. RESULTS: In all, 1047 patients were analyzed, and 69 (6.6%) fulfilled criteria for classical familial melanoma (two or more first-degree relatives diagnosed with melanoma). Taking into account other risk factors for familial melanoma, such as multiple melanoma, pancreatic cancer in the family or second-degree relatives with melanoma, the number of patients fulfilling the criteria increased to 165 (15.8%). Using a univariate analysis, we determined that a Breslow index of less than 1 mm, negative mitosis, multiple melanoma, and a history of sunburns in childhood were more frequent in familial melanoma patients, but a multivariate analysis revealed no differences in any pathological or clinical factor between the two groups. CONCLUSIONS: Similar to that observed in other countries, familial melanoma accounts for 6.6% of melanoma diagnoses in Spain. Although no differences in the multivariate analysis were found, some better prognosis factors, such as Breslow index, seem more frequent in familial melanoma, which reflect a better early detection marker and/or a different biological behavior.